Pilot Study Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapies
Latest Information Update: 08 Sep 2025
At a glance
- Drugs Nusinersen (Primary) ; Onasemnogene-abeparvovec (Primary) ; Risdiplam (Primary)
- Indications Spinal muscular atrophy
- Focus Therapeutic Use
Most Recent Events
- 15 Aug 2025 Planned End Date changed from 1 Nov 2026 to 1 Mar 2027.
- 15 Aug 2025 Planned primary completion date changed from 1 May 2026 to 1 Sep 2026.
- 15 Aug 2025 Planned initiation date changed from 1 Aug 2025 to 1 Oct 2025.